In a groundbreaking development, researchers at AIG Hospital in Hyderabad have unveiled an innovative Artificial Intelligence (AI)-based tool designed to detect fatty liver disease with remarkable accuracy and affordability. This tool can identify fatty liver disease with an accuracy rate of 95-96%, utilizing standard blood tests and basic body measurements, thereby dramatically reducing the cost of screening from ₹5,000 to just ₹500.
The AI tool was developed through collaboration between AIG Hospital and the Indian School of Business, Hyderabad. It employs four common blood parameters—Complete Blood Count, Liver Function Test, HbA1c, and Lipid Profile—in conjunction with Body Mass Index (BMI) and waist circumference measurements. By analyzing these factors, the AI model can predict both steatosis (fat accumulation) and fibrosis (hardening of the liver), which are traditionally diagnosed using costly machines like FibroScan, valued over ₹1.2 crore.
“Our model not only identifies the presence of fatty liver disease but also assesses the potential progression to fibrosis. We’ve validated this methodology with over 10,000 patients,” stated Dr. Rakesh Kalapala, Director of Endoscopy at the Centre for Obesity and Metabolic Therapy.
Fatty liver disease, previously perceived as a benign condition, is now recognized as a significant risk factor for various cardiometabolic disorders, including diabetes, heart disease, and liver cancer. According to Dr. D. Nageshwar Reddy, Chairman of AIG, “Fatty liver serves as a crucial indicator of overall health, with many individuals who have the condition succumbing to heart issues rather than liver failure.”
A notable finding from the hospital’s studies indicates that approximately 70% of patients with diabetes also have fatty liver disease, emphasizing the intertwined nature of these health issues.
Currently, the AI tool is being rolled out in the states of Telangana and Andhra Pradesh, aiming to enhance community-level healthcare accessibility. As Dr. Merugu Chandhana, an endocrinologist at AIG, pointed out, the strategic deployment of this tool could lead to earlier diagnoses and more effective of fatty liver disease, potentially saving countless lives.
Despite ongoing research efforts, there remains an absence of approved pharmacological treatments specifically for fatty liver disease in India; thus, the primary recommended intervention continues to focus on lifestyle modifications. Dr. Chandhana revealed that even a modest weight loss of 5% can diminish liver fat, while 10% may reverse liver fibrosis.
-Raja Aditya




